Aripiprazole
Product Images NDC 50090-5840

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-5840). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals in AUC and Cmax values of Aripiprazole when co-administered with various inhibitors, inducers, and other drugs. The x-axis represents change relative to reference (without interacting drug) from 0.0 to 3.0. Included drugs are CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others like valproate, lithium, and lorazepam.*

FDA Label Image

Figure2 (Figure2)

A pharmacokinetic chart showing the effect of various other drugs on Aripiprazole by illustrating the fold change and 90% confidence intervals for dehydro-Aripiprazole. The chart plots change relative to reference (without interacting drug) on the x-axis, highlighting impacts of CYP3A4 and CYP2D6 inhibitors, a CYP3A4 inducer, gastric acid blockers, and other drugs on Aripiprazole exposure parameters AUC and Cmax.*

FDA Label Image

Figure3 (Figure3)

A forest plot showing the effect of Aripiprazole on various other drugs, illustrating fold changes and 90% confidence intervals in pharmacokinetic parameters such as AUC, Cmax, and other measures relative to reference values without interacting drugs.*

FDA Label Image

Figure4 (Figure4)

A chart titled 'Aripiprazole Fold Change and 90% CI' illustrating pharmacokinetic data comparing various special populations. It shows fold changes and confidence intervals for AUC and Cmax parameters in CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment relative to reference values.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic chart showing the fold change and 90% confidence interval for dehydro-aripiprazole levels relative to reference in various subgroups. It compares CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, with axes labeled for AUC and Cmax values and change relative to reference.*

FDA Label Image

Structure (Structure)

Chemical structure of Aripiprazole showing the arrangement of chlorine-substituted aromatic rings, piperazine ring, and other functional groups typical of this antipsychotic compound.*

FDA Label Image

Camberlogo (Camber Logo)

FDA Label Image

Figure 6 (Figure 6)

A line graph comparing the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The vertical axis represents the proportion with relapse, and the horizontal axis indicates days from randomization up to 182. The Aripiprazole group shows a consistently lower relapse proportion compared to the placebo group. The number of subjects at risk is listed below the horizontal axis for each group at different time points.*

FDA Label Image

Figure 7 (Figure 7)

A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over 182 days from randomization. The chart compares Aripiprazole (solid line) versus placebo (dashed line). The proportion of relapse is lower in the Aripiprazole group throughout the study period. The number of subjects at risk decreases over time, shown for both groups below the x-axis.*

FDA Label Image

Figure 8 (Figure 8)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 364 days from randomization. The graph compares Aripiprazole and Placebo groups, with the Aripiprazole group represented by a solid line and the Placebo group by a dashed line. Below the x-axis is the number of subjects at risk at multiple time points for both groups.*

FDA Label Image

Label Image (Lbl500905840)

Packaging label for Aripiprazole 5 mg tablets by A-S Medication Solutions. The label indicates 32 unit dose tablets, storage instructions at 68 to 77 degrees Fahrenheit, and includes NDC 50090-5840-0. It also features a QR code and dispensing instructions to see the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.